Eiger BioPharmaceuticals, Inc.

Equities

EIGR

US28249U2042

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 15:55:01 2024-07-17 EDT			5-day change	1st Jan Change
12.99 ^USD	-3.42%		+9.62%	+92.87%

07-10	Amylyx Pharmaceuticals Acquires Avexitide From Eiger BioPharmaceuticals for $35 Million	MT
07-09	Spruce Biosciences, Inc. completed the acquisition of Substantially all of rights, title, interests, assets in Avexitide of Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $10 million.	CI

EIGER BIOPHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)

January 07, 2020 at 08:12 am

Item 5.02 Departure of Directors and Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain


          Officers.


(b) Departure of Director.

On January 6, 2020, Eiger BioPharmaceuticals, Inc. (the "Company") appointed Eldon Mayer as Executive Vice President and Chief Commercial Officer of the Company, effective as of January 6, 2020.

In connection with this appointment, Mr. Mayer resigned as a member of the board of directors of the Company, effective as of January 6, 2020. Mr. Mayer's departure from the board of directors of the Company is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

--------------------------------------------------------------------------------

Latest news about Eiger BioPharmaceuticals, Inc.

Amylyx Pharmaceuticals Acquires Avexitide From Eiger BioPharmaceuticals for $35 Million	07-10	MT
Spruce Biosciences, Inc. completed the acquisition of Substantially all of rights, title, interests, assets in Avexitide of Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $10 million.	07-08	CI
Moshe Arkin Engages with Eiger BioPharmaceuticals	07-01	CI
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar	06-21	RE
Spruce Biosciences, Inc. stalking horse asset purchase agreement to acquire Substantially all of rights, title, interests, assets in Avexitide of Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $10 million.	06-13	CI
Sentynl Therapeutics, Inc. acquired Global rights to Zokinvy Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $45.2 million.	05-07	CI
Zydus Lifesciences Arm Acquires Eiger BioPharmaceuticals' Progeria Drug	05-06	MT
Eiger Biopharmaceuticals, Inc. Announces Resignation of William G. Kachioff as Chief Financial Officer	05-02	CI
Eiger Biopharmaceuticals, Inc. Appoints Douglas Staut to Serve as the Company's Chief Restructuring Officer	05-02	CI
Motion for Asset Sale Approved for Eiger BioPharmaceuticals, Inc.	04-24	CI
Selection of Successful Bidder Filed by Eiger BioPharmaceuticals, Inc.	04-19	CI
Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from NASDAQ Composite Index	04-09	CI
Eiger BioPharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-08	CI
Bidding Procedure Approved for Eiger BioPharmaceuticals, Inc.	04-05	CI
Motion for Joint Administration Approved for Eiger BioPharmaceuticals, Inc.	04-05	CI
Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from S&P TMI Index	04-03	CI
Eiger BioPharmaceuticals, Inc. Announces Resignation of Jeffrey S. Glenn as Member of the Board of Directors	04-03	CI
Health Care Down as Obesity-Drug Optimism Fades -- Health Care Roundup	04-01	DJ
Sector Update: Health Care Stocks Slide Late Afternoon	04-01	MT
Top Midday Decliners	04-01	MT
Sector Update: Health Care	04-01	MT
Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection; Shares Fall	04-01	MT
Motion for Asset Sale Filed by Eiger BioPharmaceuticals, Inc.	04-01	CI
Motion for Joint Administration Filed by Eiger BioPharmaceuticals, Inc.	04-01	CI
Eiger BioPharmaceuticals, Inc. Filed for Bankruptcy	04-01	CI

Chart Eiger BioPharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. Its HDV platform includes lonafarnib, an oral farnesylation inhibitor that targets a critical host process involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV, Combination Therapy for HDV, and Peginterferon Lambda (lambda) for COVID-19. LNF is an orally bioavailable, farnesylation inhibitor that has completed a Phase 3 clinical trial for HDV infection. LNF has demonstrated dose-dependent activity in reducing HDV viral load both as a monotherapy and in combination with ritonavir (RTV) and/or PEG IFN-alfa-2a. Lambda is a type III, well-tolerated interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
EIGER BIOPHARMACEUTICALS, INC.	+92.87%	19.24M
MODERNA, INC.	+24.74%	47.54B
IQVIA HOLDINGS INC.	-0.47%	41.96B
LONZA GROUP AG	+48.83%	41.55B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	30.36B
ICON PUBLIC LIMITED COMPANY	+17.96%	27.61B
CELLTRION, INC.	-4.47%	28.7B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.7B
MEDPACE HOLDINGS, INC.	+42.56%	13.51B
BIO-TECHNE CORPORATION	+1.46%	12.34B

Other Biotechnology & Medical Research